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Background: Cancer of unknown primary site (CUP) is considered an aggressive metastatic disease but whether
the prognosis differs from metastatic cancers of known primary site is not known. Such data may give insight into
the biology of CUP and the metastatic process in general.
Methods: 6,745 cancer patients, with primary metastatic cancer at diagnosis, were identified from the Swedish
Cancer Registry, and were compared with 2,881 patients with CUP. Patients were diagnosed and died between
2002 and 2008. The influence of the primary site, known or unknown, on survival in patients with metastases at
specific locations was investigated. Hazard ratios (HRs) of death were estimated for several sites of metastasis, where
patients with known primary sites were compared with CUP patients.
Results: Overall, patients with metastatic cancers with known primary sites had decreased hazards of death
compared to CUP patients (HR = 0.69 [95% CI = 0.66–0.72]). The exceptions were cancer of the pancreas
(1.71 [1.54–1.90]), liver (1.58 [1.36–1.85]), and stomach (1.16 [1.02–1.31]). For individual metastatic sites, patients with
liver or bone metastases of known origin had better survival than those with CUP of the liver and bone. Patients
with liver metastases of pancreatic origin had an increased risk of death compared with patients with CUP of the
liver (1.25 [1.06–1.46]). The median survival time of CUP patients was three months.
Conclusions: Patients with CUP have poorer survival than patients with known primaries, except those with brain
and respiratory system metastases. Of CUP sites, liver metastases had the worst prognosis. Survival in CUP was
comparable to that in metastatic lung cancer. The aggressive behavior of CUP may be due to initial
immunosuppression and immunoediting which may allow accumulation of mutations. Upon escape from the
suppressed state an unstoppable tumor spread ensues. These novel data on the epidemiology of the metastatic
process at the population level demonstrated large survival differences in organ defined metastases depending on
the original cancer.
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Cancer possesses, by definition, the potential to metastasize
and most cancer patients die of metastasis, against which
even modern therapies often feature limited utility [1,2]. A
large proportion of fatal cancers, such as pancreatic, liver,
lung and stomach cancers present with distant metastasis
at diagnosis. For these and other cancers the size of the* Correspondence: k.hemminki@dkfz.de
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reproduction in any medium, provided the orprimary tumor shows some correlation with the likelihood
of detecting distant metastasis [3,4]. The TNM classifica-
tion, considering the size of the primary tumor and metas-
tasis to lymph nodes or distant sites, provides a prognostic
prediction of the outcome even though the classification
does not consider the organs of metastatic growth. The
lack of therapeutic success against cancer metastasis is par-
tially due to the limited understanding of the metastatic
process [4-6]. Epidemiological approaches to metastatic
cancer are hampered by the fact that cancer registries
almost invariably only consider the primary tumor and theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cluded from the TNM status, if recorded by the registry.
Consequently, population-based survival studies are
usually not able to consider the site of metastasis and
even death certificates give the primary cancer as an
underlying cause of death. Hospital discharge data have
been used to obtain information on metastasis in the
treated patients but there may be concerns about cover-
age and accuracy even if nation-wide data were avail-
able, as through the Medicare system in the USA and
the national Hospital Discharge Register in Sweden [7,8].
Data on metastatic sites may be recorded in hospital-
based registers or in clinical trials but these may not be
generalizable to the population at large [9-11].
We have found two possibilities to access metastasis
data at a nation-wide level. International Classification
of Diseases (ICD) version 9 and subsequent versions pro-
vide information on metastatic sites as multiple causes of
death, available at the Swedish Causes of Death Register.
These data are highly reliable [12], partially because of the
high proportion of deaths take place at hospitals [13], but
also due to the fact that almost 95% of death certificates in
cancer patients are based on examination at hospital prior
to death [14]. We use here this source in combination with
the TNM data to define survival in common cancers based
on the site of metastasis. The other source to metastatic
cancer is through cancer of unknown primary site (CUP).
For CUP, ICD-9 indicates the location of metastasis
according to affected lymph nodes or organ sites, because
the primary tumor is not known [7]. Furthermore, accord-
ing to the Swedish Causes of Death Register, the under-
lying cause of death for CUP patients is usually the cancer
of the organ system that has killed the patient, i.e., the fatal
metastatic site, as judged by the death registrar. This prac-
tice is different from all other cancers but it will provide
useful information for the study of the metastatic process.
In this study we compare survival times for organ-
specific metastasis from known primary cancers and from
CUP. We hypothesize, in view of the aggressive behavior
of CUP, that CUP patients have a worse survival than
those with metastatic cancers with known primaries. A
counter-hypothesis posits that the survival may be better
for CUP because the immunological or other mechanisms
that forced the involution of the primary tumors in CUP
might also control the spread of metastasis [15]. CUP
patients with brain metastasis have indeed survived better
than those with other brain metastases [8,16]. However,
the data are lacking for extracranial sites and the present
study provides novel population-based results for all com-
mon cancers and their metastases.
Methods
Cancers were identified from the Swedish Cancer Registry,
which is based on the compulsory notification of cancercases. Cancer cases in the Database were coded according
to ICD-7 since 1958, ICD-9 since 1987 and ICD-10 since
1993. ICD-9 and ICD-10 codes are translated back to
ICD-7. However, only ICD-9 and ICD-10 coding allow
identification of the site of CUP. Causes of death were
obtained from the Swedish Cause of Death Registry, which
used ICD-10 coding since 1997 [17]. National Census
Data were included into the dataset to obtain information
on socioeconomic status and geographical location of resi-
dence on each individual. Linking the databases was made
possible by using the national 10-digit civic identification
number, given to each person in Sweden for his or her life-
time. In order to provide anonymity, the identification num-
ber has been replaced by a serial number for each person.
We investigated survival in eight common metastatic
cancers, which were identified by their ICD-7 codes:
lung cancer (162,163), colorectal cancer (153,154.0),
prostate cancer (177, only men), pancreatic cancer (157),
liver cancer (155), stomach cancer (151), breast cancer
(170, only women), kidney cancer (180), and bladder
cancer (181.0). ICD-10 codes used in identifying metas-
tases from death certificates and CUPs from the cancer
registry are discussed below. When a CUP diagnosis is
made, the metastases are often already present in mul-
tiple locations [15]. Inclusion of CUP patients with only
one distant metastasis at diagnosis was desired. There-
fore, CUP patients with or more than one primary can-
cer or one remark of metastasis in the death certificate
were excluded from the reference (CUP) group. Further-
more, we also restricted all included cancer cases to those
with 1) positive distant metastasis status upon diagnosis
and 2) only one mentioned metastasis in their death certifi-
cate. Thus, we may assume that specific metastases men-
tioned in death certificate were present at diagnosis. ICD-
10 codes used for identifying CUP locations were the
following: Any location (C76, C78, C79), brain (C79.3),
bone (C79.5), gastro-intestinal (C78.4-8, except .7), liver
(C78.7), and respiratory system (C78.0-3).
Follow-up of cancer patients started at diagnosis, and
terminated at death. Because the TNM classification has
been available since 2002, analyses were restricted to
patients receiving a cancer diagnosis during 2002 or later.
All deaths occurred until the end of 2008. Only patients
that survived at least one month were included. A Cox re-
gression hazard model was used to calculate HRs for death,
where cancer patients with metastasis upon diagnosis (M1)
with known primary sites were compared with a reference
group, encompassing patients with CUP with defined
organ metastasis. Age (months) was the underlying time
scale. The statistical model included socio-economic
index, gender and geographical location of residence as
covariates. All calculations were performed with SAS-
software (PROC PHREG; SAS Version 9.2; SAS Institute,
Cary, NC).
Table 1 Risks of death for metastatic cancers compared
to CUP (cancer of unknown primary) patients diagnosed
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Primary site N HR 95% CI
CUP (reference) 2881 1
Colorectal cancer 1438 0.61 0.57 0.65
Pancreatic cancer 460 1.71 1.54 1.90
Stomach cancer 322 1.16 1.02 1.31
Liver cancer 188 1.58 1.36 1.84
Lung cancer 2453 0.98 0.92 1.04
Kidney cancer 284 0.71 0.62 0.80
Bladder cancer 139 0.93 0.78 1.11
Prostate cancer 1259 0.24 0.22 0.26
Breast cancer 202 0.53 0.45 0.61
All known primaries 6745 0.69 0.66 0.72
Patients were diagnosed and died between 2002 and 2008. Only patients with
one primary cancer and a positive metastasis status were considered.Results
A total of 158,670 patients with cancer of lung, colorec-
tum, prostate, pancreas, stomach, breast, kidney, and
bladder diagnosed between 2002 and 2008 were identi-
fied. Of these patients, 50,074 died during the study
period, and 14,698 had metastatic cancer at diagnosis
(M1). After excluding cancer patients with multiple
metastases and deaths occurring within one month after
diagnosis, 6,745 cancer patients were selected for the ana-
lyses. The reference group consisted of 2,881 CUP patients
with a single metastasis. Of the included metastatic sites,
survival was worst for CUP of the liver (Figure 1). Median
survival times (in months) for the different locations of
CUP were as follows: 4 for respiratory, other gastro-
intestinal and brain; 2 for liver; and 3 for bone.
HRs for death were assessed, comparing metastatic
cancers with a known primary location with CUP at corre-
sponding locations. All patients with metastatic cancer were
compared, irrespective of metastatic location (Table 1).
Patients with metastatic cancer from a known primary had
a decreased risk of death compared to patients with any
CUP (HR= 0.69). Patients with metastatic pancreatic, liver,
and stomach cancer had an increased risk of death com-
pared with CUP patients with metastases at these locations,
whereas patients with metastatic colorectal, kidney, breast,
and prostate cancer had a decreased risk of death compared
with CUP patients. Survival in CUP with lung metastases
was similar to that in metastatic lung cancer.Figure 1 Kaplan-Meier survival curves for death in CUP, depending o
Red = liver. Green = brain. Yellow = gastro-intestinal. Black = respiratory, BlNext, individual metastatic sites were analyzed (Table 2).
The liver was the most common CUP metastasis site (983
cases). Patients with known primary cancers were at a
decreased risk of death compared to those with CUP
when the organ of metastasis was the liver (0.58), bone
(0.57), or gastro-intestinal organs (0.78). Survival from
respiratory and brain metastases was similar in patients
with CUP and patients with known primaries. Patients
with pancreatic liver metastases were found to be at an
increased risk of death (1.24) compared to patients with
CUP of the liver. However, patients with colorectal and
lung cancer had decreased risks of death. Patients withn the site of CUP metastases. Median survival times are displayed.
ue = bone.
Table 2 Risks of death for metastatic cancers compared to CUP (cancer of unknown primary) patients diagnosed with these metastases
Site of metastasis
Respiratory system Gastro-intestinal system Liver Brain Bone
Primary site N HR 95% CI N HR 95% CI N HR 95% CI N HR 95% CI N HR 95% CI
CUP (reference) 286 1 878 1 983 1 131 1 215 1
Colorectal cancer 38 0.44 0.30 0.64 46 0.67 0.49 0.93 587 0.42 0.37 0.46 11 0.28 0.13 0.60 6 0.80 0.32 2.04
Pancreatic cancer 21 1.61 0.92 2.81 11 0.75 0.38 1.47 235 1.24 1.06 1.46 2 5.69 0.70 46.11 3 0.75 0.17 3.19
Stomach cancer 6 2.76 1.01 7.54 23 1.51 0.94 2.45 110 0.98 0.78 1.23 2 1.45 0.21 9.77 12 0.88 0.38 2.03
Liver cancer 14 1.17 0.60 2.26 8 0.75 0.33 1.68 73 1.19 0.92 1.55 1 3.34 0.19 58.65 8 0.56 0.21 1.47
Lung cancer 71 1.36 0.99 1.87 10 0.68 0.36 1.32 166 0.76 0.63 0.90 574 1.00 0.81 1.23 317 0.99 0.81 1.22
Kidney cancer 45 0.65 0.44 0.97 0 0.00 0.00 0.00 11 0.50 0.26 0.96 7 0.72 0.24 2.17 31 0.81 0.50 1.30
Bladder cancer 18 0.83 0.46 1.50 1 7.70 0.83 71.62 7 1.44 0.65 3.19 5 0.64 0.15 2.65 20 0.95 0.52 1.71
Prostate cancer 8 0.42 0.13 1.37 1 0.11 0.01 0.90 14 0.25 0.14 0.45 6 0.48 0.11 2.16 481 0.27 0.21 0.34
Breast cancer 15 0.83 0.37 1.84 1 0.29 0.04 2.13 13 0.31 0.16 0.58 9 0.66 0.15 2.87 26 0.50 0.29 0.87
All known primaries 236 0.83 0.68 1.01 101 0.78 0.62 0.99 1216 0.58 0.53 0.63 617 0.95 0.78 1.17 904 0.57 0.48 0.69
Patients were diagnosed and died between 2002 and 2008. Only patients with one primary cancer and a positive metastasis status were considered.
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Figure 2 (See legend on next page.)
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Figure 2 Kaplan-Meier survival curves for death, depending on the primary site of metastatic cancer. (A) Death in any metastatic location
from indicated primary cancers or CUP, (B) death in liver metastases from indicated primary cancers or CUP, and (C) death in metastases to
respiratory organs from indicated primary cancers or CUP.
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patients. The exception was patients with liver metastases,
with lung cancer patients having a decreased risk of death
compared to CUP patients. For most metastatic locations,
colorectal, kidney, prostate, and breast cancer patients had
a decreased risk of death compared with CUP patients
with corresponding metastases. Bone metastases originat-
ing from the prostate seem to have exceptional prognosis
compared with CUP of bone.
The Kaplan-Meier plots in Figure 2 illustrate survival
from metastatic cancer depending on the primary site.
Among the indicated primary cancers and CUP, without
regard to the metastatic location, survival was poor for
pancreatic cancer compared with colorectal cancer
(Figure 2A). Among the indicated primary cancers with
liver metastases, lung and colorectal cancers showed better
survival than CUP of liver (Figure 2B). In the case of re-
spiratory metastases, colorectal and kidney cancer patients
had better survival than patients with CUP (Figure 2C).
Discussion
Population-based cancer registries are important sources
of data for cancer control. However, most cancer regis-
tries lack data on the location of metastases and thus
they have inherent weaknesses in following the process
that eventually kills the patient. In this paper we present
some alternative sources of data in order to address
questions about survival depending on the location of
metastasis. We investigated survival of patients with
metastases from known primaries, compared with CUP
patients, whose primaries were by definition unknown.
Overall, survival in metastatic cancer was better if the
primary location was known. However, metastatic pan-
creatic, liver, and stomach cancers –known for their
poor prognosis- overall featured worse survival than
CUP. The present results show 1) variations in risks of
death in patients with defined metastases depending on
the primary site of the malignancy, and that 2) survival
in CUP is generally worse than with primary cancers
metastatic to the same organ where CUP was detected.
This may be due to the aggressive behavior of CUP.
Although the primary tumor in CUP is thought to be
dormant, CUP patients feature early distant metastases
[15,18,19]. The metastatic tendency may explain the
poor prognosis, and, as in primary cancers, metastases
are thought to be the cause of death in most cancer
patients [1,2,7]. Several genes have been implicated in
metastasis [6,20,21]. Indeed, some important metastaticgenes have been shown to be overexpressed in CUP:
vessel endothelial growth factor, which induces angio-
genesis [21], and matrix metalloproteinases, proteolytic
enzymes mediating local invasion and metastasis [20].
The estimations of median survival times for included
CUP patients, three months, is consistent with previous
reports of approximately three to four months in
population-based studies [8,15,22]. It has been earlier
noted that some hospital-based studies have estimated
substantially longer CUP survival, probably due to differ-
ent inclusion criteria [22]. Although the prognosis of
CUP is overall poor, some 15–20% of the patients
present with less aggressive and/or treatable tumors of
favorable prognosis [23]. Some of these include CUP
diagnosed in lymph nodes only and others require clin-
ical information not available in the present study, in-
cluding some colorectal and breast cancers. The present
metastatic sites would largely belong to the 80–85% of
CUP on unfavorable prognosis. Although therapies have
improved, particularly in the favorable subset, there has
been no evidence that the overall survival would have
changed, unfortunately alike many metastatic cancers
[24,25]. Fast diagnosis is important in CUP and new
methods include immunohistochemical and gene ex-
pression based methods for tissue-of-origin identifica-
tion [23,26,27]. If the primary cancer can be identified
the diagnosis is changed to that cancer which would not
be scored as CUP in the present analysis. CUP incidence
has been declining during the past decade in many
countries and improved detection of primary cancers
may have contributed to this trend [25].
Recently, patients with CUP of brain have been shown
to have better survival (HR = 0.85/0.79 men/women)[8]
compared to patients with known primaries. However,
other investigators have not found any difference in
brain metastasis survival between patients with a known
or unknown primary location [16]. In the present study,
no differences could be found. Lung cancer was the most
common source of brain metastases in the present study.
Thus, we speculate that the primary source of CUP of the
brain may in fact often be lung cancer, which is also the
most common cause of death in CUP patients [18].
In our dataset of CUP patients, CUP of liver featured
the shortest median survival, only two months. The poor
prognosis of liver involvement in CUP is known: previ-
ous estimates have ranged between 1.7 and 10 months
[19,28]. Similarly, CUP patients with liver involvement
have been shown to be at an increased risk of death
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involvement. Histological features consistent with neu-
roendocrine carcinoma have been associated with sig-
nificantly better prognosis than adenocarcinoma. Liver
metastases commonly arise from colorectal cancer, and the
five year survival in patients not receiving surgery has been
reported to be less than 5% [29]. More recently, the five
year survival in selected groups receiving surgery may
approach 50% [30]. The HR for colorectal cancer with liver
metastasis was 0.42 but those from prostate (0.25) and
breast (0.31) cancer were even more favorable. Pancreatic
cancer, frequently featuring liver metastases, is associated
with a dismal prognosis. Survival in patients with pancre-
atic liver metastases has been approximated to less than
three months [31]. However, median survival in patients
receiving surgery has been estimated to 11.4 months [32].
Novel developments regarding chemotherapeutic regimens
in selected patients also show promising results [33].
The skeletal system has been described as the most
common site for metastases [34]. Present results show that
patients with skeletal lung cancer metastases had similar
risks of death than CUP of bone. The prognosis among
lung cancer patients with bone metastases was unfavor-
able. Previous results are in line with our findings, the
median survival being only three months even in patients
receiving surgical treatment [35]. Remarkably, the HR for
prostate cancer was only 0.27 and those of kidney and
breast cancer were 0.51 and 0.50, respectively.
Our study has several strengths. We used a national
database, considered to be close to 100% complete in can-
cer registration [17]. Population-based studies on meta-
static cancers may encounter problems regarding exclusion
of the metastatic sites in the TNM-coding system. The
Database used in the present study incorporates data from
both the Swedish Cancer Registry and the Swedish Cause
of Death Registry. Therefore, we could use the death certi-
ficates of cancer patients to identify the locations of metas-
tases. The validity of death certificates in Sweden has a
considerable impact on the reliability of our results. In
Sweden, the proportion of deaths occurring in hospitals is
very high. In 2003, 62.5% of deaths occurred in hospitals,
whereas the rest occurred in other health care facilities
(nursing homes, hospices etc.) or at home [13]. Further-
more, when considering only deaths with malignancies as
the underlying cause, the proportion of hospital death has
been shown to be as high as 85.1%. In hospital deaths, the
issuing doctor of the death certificate is likely to have
been involved in the treatment of cancer patients and
therefore have insight in the patient’s history. Therefore,
we believe that the high number of hospital deaths in
Sweden strengthens the validity of death certificates.
Also, the validity of death certificates with a malignancy
as the underlying cause has been thought to be among
the highest [12].Can we be sure that the metastases mentioned in the
death certificate were present at the time of diagnosis?
This issue was addressed by only including cancer
patients with positive distant metastatic status at diagno-
sis. Moreover, we excluded from our analyses decedents
with more than one metastasis mentioned in their death
certificate. Finally, in order to exclude the possibility that
metastases might have been seeded from another pri-
mary site, we also excluded cancer cases with primary
cancer diagnoses at multiple sites. Naturally, restriction
of investigations to cancer patients with metastases at
only one defined organ had a substantial impact on the
number of cases available for analysis.
The poor survival in CUP may be due to its aggressive
behavior. CUPs may undergo substantial phenotypic
changes in order to avoid immunological surveillance,
and the primary tumor may in fact reside in the same
organ as the metastases themselves [18]. Among differ-
ent sites, CUPs of the liver have the worst prognosis. It
is tantalizing to speculate that this is linked to the im-
mune hypothesis relating to CUP [18]. If many CUP
cases are indeed due to prior immunological eradication
of the primary, and CUP metastases thus represent im-
munological escape variants, it is perhaps logical that
their growth is fastest in the liver, which has been pro-
posed an “immune suppressive organ” [36]. Overall, the
survival of CUP patients was shorter than with patients
with known primaries. This is compatible with CUP
representing tumors subjected to significant prior immu-
noediting and/or featuring a high degree of immunosup-
pression. A tumor initially sensitive to immunological
control might have ample time to become more malignant
through accumulation of hundreds of mutations during a
prolonged equilibrium phase [37]. Upon escape from the
equilibrium state an unstoppable killer is then unleashed.
CUP accounts for 3–5% of cancer diagnoses, and although
it is associated with a bad prognosis, some chemothera-
peutic regimens have shown promising results [38-40].
Further research is motivated in order to increase under-
standing of this large group of cancer patients.
Conclusions
CUP at many metastatic locations featured poorer progno-
sis than metastatic cancers with a known primary location
and survival in CUP was comparable to that of metastatic
lung cancer. As another novel finding, we showed large
survival differences in patients with defined organ metasta-
sis depending on the primary tumor.
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